The Role of Dietary Protein on Lipotoxicity

Nutrition Reviews

Volumn 65, Issue SUPPL.1, 2007, Pages

  Torres, Nimbe ^a   Tovar, Armando R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Adipose tissue; Diabetes; Lipotoxicity; Obesity; Soy protein

Indexed keywords

SOYBEAN PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; LIPID METABOLISM; METABOLISM; OBESITY; PROTEIN INTAKE; REVIEW;

ANIMALS; DIETARY PROTEINS; HUMANS; LIPID METABOLISM; OBESITY; SOYBEAN PROTEINS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION, GENETIC;

EID: 34547415614     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00330.x     Document Type: Article

References (30)

1. Carmiel-Haggai M., Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005;19:S136-S138.
2. Kritchevsky D. Dietary protein, cholesterol and atherosclerosis: A review of the early history. J Nutr 1995;125:S589S-S593S.
3. Young VR. Soy protein in relation to human protein and amino acid nutrition. J Am Diet Assoc 1991;91:S828-S835.
4. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:S276-S282.
5. Zhan S., Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005;81:S397-S408.
6. Tovar AR, Murgufa F., Cruz C., et al. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cyto-kines in rats with chronic nephritic syndrome. J Nutr 2002;132:S2562-S2569.
7. Sirtori CR, Agradi E., Conti F., Mantero O., Gatti E. Soybean-protein diet in the treatment of type-II hy-perlipoproteinaemia Lancet 1977;1:S275-S277.
8. Torres N., Torre-Villavazo I., Tovar AR. Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders. J Nutr Bio-chem 2005;17:S365-S373.
9. McCarty MF. Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Med Hypotheses 1999;53:S459-S485.
10. Assan R., Attali JR, Ballerio G. Glucagon secretion induced by natural and articial amino acids in the perfused rat pancreas. Diabetes 1977;26:S300-S307.
11. Foretz M., Pacot C., Dugail I., et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 1999;19:S3760-S3768.
12. Shimomura I., Bashmakov Y., Ikemoto S., Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999;96:S13656-S13661.
13. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:S1125-S1131.
14. Matsuda M., Korn BS, Hammer RE, et al. SREBP clevage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 2001;15:S1206-S1216.
15. Shimano H., Shimomura I., Hammer RE, Herz J., Goldstein JL, Brown MS, Horton JD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997;100:S2115-S2124.
16. Ascencio C., Torres N., Isoard-Acosta F., et al. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 2004;134:S522-S529.
17. Miserez AR, Cao G., Probst LC, Hobbs HH. Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2). Genomics 1997;40:S31-S40.
18. Tovar AR, Torre-Villavazo I., Ochoa M., et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005;46:S1823-S1832.
19. Tovar AR, Murguía F., Cruz C., et al. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cyto-kines in rats with chronic nephrotic syndrome. J Nutr 2002;132:S2562-S2569.
20. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:S1844-S1850.
21. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:S147-S152.
22. Adams LA, Angulo P., Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:S899-S905.
23. Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Bio-chimie 2005;87:S57-S64.
24. Torres N., Torre-Villalvazo I., Tovar AR. Future directions in reducing hepatic lipotoxicity. Future Lipidol 2006;1:S331-S341.
25. Mezei O., Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003;133:S1238-S1243.
26. Nadler ST, Attie AD. Please pass the chips: Genomic insights into obesity and diabetes. J Nutr 2001;131:S2078-S2081.
27. Cock TA, Houten SM, Auwerx J. Peroxisome prolif-erator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 2004;5:S142-S147.
28. Noriega-López LG, González-Granillo M., Tovar AR, Torres N. Soy protein reduces insulin secretion through regulation of PPAR gamma, PPAR alpha, and GLUT 2 expression in pancreatic islets of obese rats. FASEB J 2006;20:SA596.
29. Torres N., Palacios-González B., Noriega-López L., Tovar AR. Índice glicémico, Índice insulinémico y Carga glicémica de bebidas de soya con un con-tenido bajo y alto en hidratos de carbono. Rev Invest Clin 2006;58:S487-S497.
30. Mikkelsen PB, Toubro S., Astrup A. Effect of fat-reduced diets on 24 h energy expenditure: compris-ons between animal protein, vegetable protein, and carbohydrate. Am J Clin Nutr 2000;72:S1135-S1141.